Galapagos enters into oncology target discovery collaboration with Janssen Pharmaceutica
The goal of the new collaboration will be to discover and validate novel targets in the field of oncology. BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation. Target discovery in cutting edge in vitro assays may provide novel drug targets for cancer areas with an unmet medical need. BioFocus DPI receives an upfront payment of EUR2.9 million. In total, BioFocus DPI may receive additional research, acceptance, license and development fees of up to EUR7.6 million should certain predetermined criteria be achieved.
"This marks BioFocus DPI's first target discovery agreement in oncology, as well as the largest target discovery agreement to date for the service division," said Onno van de Stolpe, Chief Executive Officer of Galapagos.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.